Pharvaris (PHVS) director sells 10,000 shares, exercises options under 10b5-1

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Pharvaris N.V. director Elisabeth Bjork executed a scheduled option exercise and share sale under a Rule 10b5-1 trading plan. She exercised stock options for 10,000 common shares at $8.05 per share in a cashless transaction and sold 10,000 common shares at a weighted average price of $29.3166, with individual sale prices ranging from $29.03 to $29.61. Following these transactions, she holds 15,167 common shares and 11,000 stock options, which expire on April 6, 2033. The option grant vested 25% on April 6, 2024, with the remaining shares vesting in equal monthly installments thereafter.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($293,166)

Net Sell 3 txns

Insider Bjork Elisabeth

Role null

Sold 10,000 shs ($293K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$8.05	$81K
Sale	Common Stock	10,000	$29.3166	$293K

Holdings After Transaction: Stock Option (Right to Buy) — 11,000 shares (Direct, null); Common Stock — 25,167 shares (Direct, null)

Footnotes (1)

This is a scheduled exercise and sale from 10b5-1 trading plan. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $29.03 to $29.61. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Shares sold: 10,000 shares Weighted average sale price: $29.3166 per share Options exercised: 10,000 shares +5 more

8 metrics

Shares sold 10,000 shares Common stock sold on May 20, 2026

Weighted average sale price $29.3166 per share Open-market sale prices ranged $29.03–$29.61

Options exercised 10,000 shares Stock options exercised at $8.05 per share

Exercise price $8.05 per share Stock Option (Right to Buy) conversion price

Shares held after 15,167 shares Common stock beneficially owned following transactions

Options held after 11,000 options Stock options outstanding after the exercise

Option expiration April 6, 2033 Expiration date of reported stock options

Initial vesting 25% on April 6, 2024 Start of vesting for the option grant

Key Terms

Rule 10b5-1 trading plan, cashless exercise, weighted average sale price, Stock Option (Right to Buy), +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions on the reported date pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

cashless exercise financial

"shares were sold in connection with the exercise of stock options in a cashless exercise transaction"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold"

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for the option transactions"

Form 4 Insider Transactions: What Each Field Means →

05/22/2026 - 02:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bjork Elisabeth

(Last)

(First)

(Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/20/2026		M⁽¹⁾		10,000	A	$8.05	25,167	D
Common Stock	05/20/2026		S⁽¹⁾		10,000	D	$29.3166⁽²⁾	15,167	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.05	05/20/2026		M⁽¹⁾			10,000	⁽³⁾	04/06/2033	Common Stock	21,000	$0	11,000	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $29.03 to $29.61. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Elisabeth Bjork	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pharvaris (PHVS) director Elisabeth Bjork report in this Form 4?

Elisabeth Bjork reported an option exercise and share sale. She exercised options for 10,000 Pharvaris common shares at $8.05 and sold 10,000 shares at a weighted average price of $29.3166, all under a pre-arranged Rule 10b5-1 trading plan.

How many Pharvaris (PHVS) shares did the director sell and at what price?

She sold 10,000 Pharvaris common shares. The reported weighted average sale price was $29.3166 per share, with individual sale prices ranging from $29.03 to $29.61, executed as part of a cashless exercise under a Rule 10b5-1 trading plan.

What options did the Pharvaris (PHVS) director exercise in this transaction?

She exercised stock options covering 10,000 Pharvaris common shares at an exercise price of $8.05 per share. The exercise was part of a cashless transaction linked to the same Rule 10b5-1 plan that governed the related open-market share sales.

How many Pharvaris (PHVS) shares and options does the director hold after the Form 4 transactions?

After the reported transactions, she beneficially owns 15,167 Pharvaris common shares and 11,000 stock options. These figures reflect her position immediately following the exercise-and-sell sequence disclosed for the transactions dated May 20, 2026.

Were the Pharvaris (PHVS) director’s transactions made under a Rule 10b5-1 trading plan?

Yes. The filing states the exercise and related share sales were made pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged trading programs, designed to allow structured selling independent of day-to-day market conditions or new company-specific information.

What is the vesting and expiration schedule of the Pharvaris (PHVS) options involved?

The option grant vested 25% on April 6, 2024, with the remainder vesting in equal monthly installments over 48 months. The options reported in the Form 4 expire on April 6, 2033, if not exercised earlier according to the filing’s terms.